Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer
NCT07226115
Summary
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Although adjuvant chemotherapy improves survival after curative resection, its efficacy varies widely among patients. The absence of reliable predictive biomarkers often leads to overtreatment or undertreatment. This study aims to develop a machine learning-based predictive model for adjuvant chemotherapy response using tumor-derived alternative splicing signatures. By integrating RNA-seq data, splicing isoform and clinical outcomes, this study seeks to identify molecular predictors of treatment response and recurrence risk after surgery.
Eligibility
Inclusion Criteria: * Histologically confirmed stage II-III colorectal cancer (TNM classification, 8th edition) * Received standard adjuvant chemotherapy after curative resection * Availability of tumor tissue (FFPE or frozen) before chemotherapy * Sufficient clinical data for outcome analysis (recurrence, survival) * Age 18-80 years Stage Exclusion Criteria: * Inflammatory bowel disease * Inadequate RNA quality or lack of consent
Conditions5
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07226115